LYC Healthcare’s latest Q2 FY2025 results reflect steady progress, with revenue rising 29% year-on-year to RM41.74 million from RM32.01 million. This growth was driven by strong performance in its nutraceutical, clinical, and confinement businesses, alongside contributions from new subsidiaries. The group also recorded a profit before tax of RM1.55 million, a significant improvement from a loss of RM2.04 million in the same quarter last year.

Regionally, Malaysia's revenue surged by 41% to RM27.81 million (Q2 FY2024: RM19.71 million), supported by growth in confinement and nutraceutical segments, while losses before tax narrowed from RM3.51 million to RM0.77 million. Singapore's revenue grew 33% to RM16.93 million (Q2 FY2024: RM12.74 million), though profit before tax eased slightly to RM1.39 million from RM1.47 million due to higher operating costs.

While net losses attributable to owners widened to RM2.77 million, impacted by foreign exchange losses and rising costs, the group remains focused on strategic realignments, including divestments and new partnerships. These moves position LYC to leverage healthcare megatrends, despite ongoing challenges.

Price Movement Overview

• The share price of LYC Healthcare Berhad has shown a notable downtrend from April to September, declining from a high of approximately RM0.185 to a low of RM0.075.
• In recent weeks, the price appears to be stabilising around RM0.08–RM0.10, with minor upward movement indicating potential consolidation.

Key Levels

Support Level: The price found strong support at RM0.06 in September, with buyers stepping in to prevent further decline.
Resistance Level: Immediate resistance is at RM0.10, which the price is testing currently.
Breakout Potential: A sustained breakout above RM0.10 could see the share price targeting RM0.12 or higher, given the current upward momentum.